Saikat De

Saikat De

Auto-generated profile, based on publicly available information

Saikat De

Institute of Life Sciences

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
SDSaikat De
Saikat De
PMPrabhudutta Mamidi
Prabhudutta Mamidi
SGSoumyajit Ghosh
Soumyajit Ghosh
SKSupriya Suman Keshry
Supriya Suman Keshry
CMChandan Mahish
Chandan Mahish
SCSoma Chattopadhyay
Soma Chattopadhyay
Chikungunya virus (CHIKV) has reemerged as a global public health threat. The inflammatory pathways of the renin-angiotensin system (RAS) and peroxisome proliferator-activated receptor-gamma (PPAR-γ) are usually involved in viral infections.

14 December 2022 in Journal of Virology
Verified
Journal Article
Open access
SCSanchari Chatterjee
Sanchari Chatterjee
SKSameer Kumar
Sameer Kumar
PMPrabhudutta Mamidi
Prabhudutta Mamidi
ADAnkita Datey
Ankita Datey
SSSoumya Sengupta
Soumya Sengupta
SCSoma Chattopadhyay
Soma Chattopadhyay
Being intracellular parasites, viruses require several host cell machineries for effectively replicating their genome, along with virus-encoded enzymes. One of the strategies involves hijacking of the DDR pathways.

19 July 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
SDSaikat De
Saikat De
SGSoumyajit Ghosh
Soumyajit Ghosh
SKSupriya Suman Keshry
Supriya Suman Keshry
CMChandan Mahish
Chandan Mahish
CMChinmayee Mohapatra
Chinmayee Mohapatra
SCSoma Chattopadhyay
Soma Chattopadhyay
The increase in disease incidences and persistent Chikungunya virus (CHIKV)-induced arthritis have been a huge burden on public health globally. In the absence of specific antivirals or vaccines, it is essential to continue efforts to develop effective anti-CHIKV strategies.

21 December 2023 in ACS Omega
Verified
Journal Article
Open access
RDRudra Narayan Dash
Rudra Narayan Dash
ARAmrita Ray
Amrita Ray
PMPrabhudutta Mamidi
Prabhudutta Mamidi
SDSaikat De
Saikat De
TMTapas K Mohapatra
Tapas K Mohapatra
BSBharat Bhusan Subudhi
Bharat Bhusan Subudhi
There is no approved antiviral for the management of the Chikungunya virus (CHIKV). To develop an antiviral drug that can manage both CHIKV and arthritis induced by it, an ester conjugate of telmisartan (TM) and salicylic acid (SA) was synthesized (DDABT1). It showed higher potency (IC50 of 14.53 mu M) and a good selectivity index [(SI = CC50/IC50) > 33]. On post-treatment of DDABT1, CHIKV infection was inhibited significantly by reducing CPE, viral titer, viral RNA, and viral proteins. Further, the time of addition experiment revealed >95% inhibition up to 4hpi indicating its interference predominantly in the early stages of infection. However, the late stages were also affected. This conjugate of SA and TM was found to increase the antiviral efficacy, and this might be partly attributed to modulating angiotensin II (Ang II) receptor type 1 (AT1). However, DDABT1 might have other modes of action that need further investigation. In addition, the in vivo experiments showed an LD50 of 5000 mg/kg in rats and was found to be more effective than TM, SA, or their combination against acute, subacute, and chronic inflammation/arthritis in vivo. In conclusion, DDABT1 showed remarkable anti-CHIKV properties and the ability to reduce inflammation and arthritis, making it a very good potential drug candidate that needs further experimental validation.

7 October 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
ADAnkita Datey
Ankita Datey
SCSanchari Chatterjee
Sanchari Chatterjee
SGSoumyajit Ghosh
Soumyajit Ghosh
PKP Sanjai Kumar
P Sanjai Kumar
SDSaikat De
Saikat De
SCSoma Chattopadhyay
Soma Chattopadhyay
Japanese encephalitis, caused by Japanese encephalitis virus (JEV), is a vector-borne disease with no specific therapeutics available yet. Binding of angiotensin II (Ang II) to angiotensin II type 1 (AT1) receptor induces the release of inflammatory cytokines associated with viral encephalitis. Accordingly, Ang II receptor blockers (ARBs) have been proposed to manage encephalitis. Since telmisartan (TM, antagonist of AT1 and agonist of PPARγ) has relatively better brain access than other ARBs, this investigation aims to evaluate its anti-JEV efficacy in vitro and in vivo . TM reduced JEV titer, RNA, and protein (NS3) significantly in the BHK-21 cells with an IC 50 of 24.68 µM and a CC 50 of >350 µM (Selectivity Index >14.18), indicating its potential for repurposing against JEV. The anti-JEV efficacy of TM was further observed in other physiologically relevant cells. Interestingly, the viral load was reduced significantly in pre-, co-, and post-treatment conditions of TM. In the presence of GW (PPARγ antagonist) and AG (AT1 agonist), viral infection was increased remarkably, while AT1 was upregulated and PPARγ was downregulated. TM treatment reversed these levels during infection. In addition, siRNA knockdowns of AT1 and PPARγ showed an insignificant change in infection upon TM treatment. Furthermore, reduction of inflammatory markers like p-IRF-3, COX-2, and p-NF-κB was observed after TM treatment in RAW264.7 cells, suggesting its immunomodulation through the AT1/PPARγ axis. Finally, the anti-JEV potential of TM was validated in a mouse model through the reduction of disease score, viral protein, and histological changes. Thus, the preclinical efficacy of TM suggests its suitability for repurposing against JEV. IMPORTANCE: Japanese encephalitis, caused by JEV, is a vector-borne disease for which no specific therapeutics are yet available. Binding of Ang II to the AT1 receptor induces the release of inflammatory cytokines associated with viral encephalitis. Accordingly, telmisartan, which is an antagonist of AT1 and an agonist of PPARγ with better brain access, was evaluated for its anti-JEV efficacy in vitro and in vivo in the current study. Telmisartan demonstrated significant reduction in JEV titer, RNA, and protein levels in different treatment conditions. This treatment reversed the levels of AT1 and PPARγ as well as inflammatory markers, p-IRF-3, COX-2, and p-NF-κB during JEV infection, suggesting its immunomodulatory effect through the AT1/PPARγ axis. Finally, the anti-JEV potential of telmisartan was validated in a mouse model through the reduction of disease score, viral protein, and histological changes. Hence, the preclinical efficacy of telmisartan suggests its suitability for repurposing against JEV.

13 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SCSanchari Chatterjee
Sanchari Chatterjee
SKSameer Kumar
Sameer Kumar
PMPrabhudutta Mamidi
Prabhudutta Mamidi
ADAnkita Datey
Ankita Datey
SSSoumya Sengupta
Soumya Sengupta
SCSoma Chattopadhyay
Soma Chattopadhyay
Viruses utilize a plethora of strategies to manipulate the host pathways and hijack its machineries for efficient replication. Several DNA as well as handful of RNA viruses are reported to interact with proteins involved in DNA damage responses (DDR). As the DDR pathways have never been explored in Alphaviruses, this investigation intended to determine the importance of the DDR pathways in CHIKV infection through in vitro, in vivo and ex vivo models. The study reveals that CHIKV infection activates the Chk2 and Chk1 proteins associated with DDR signaling pathways and increases DNA damage by 95%. Inhibition of both ATM-ATR kinases by ATM/ATR kinase inhibitor (AAKi) shows drastic reduction in viral particle formation in vitro. Next, the treatment of mice with this drug has been shown to reduce the disease score substantially in CHIKV-infected C57BL/6 mice with 71% decrement in the viral copy and the same has been established in hPBMC-derived monocyte-macrophage populations. Additionally, gene silencing of Chk2 and Chk1 reduces viral progeny formation around 73.7% and 78% respectively. Moreover, it has been demonstrated that CHIKV-nsP2 interacts with Chk2 and Chk1 during CHIKV infection and docking analysis depicts the specific amino acids responsible for these interactions. Further, the data suggests that CHIKV infection induces cell cycle arrest in G1 and G2 phases. In conclusion, this work demonstrated for the first time the mechanistic insight of the induction of DDR pathways by CHIKV that might contribute to the designing of effective therapeutics for the control of this virus infection in future. IMPORTANCE: Viruses being intra-cellular parasite, need several host cell machineries so as to achieve effective replication of their own genome, along with virus-encoded enzymes. One of the strategies is to hijack the DDR pathways. Several DNA as well as handful of RNA viruses interact with the cellular proteins involved in DDR pathways, however, reports with respect to the association of Chk2 and Chk1 in alphavirus infection are scanty. Hence, this study is amongst the first to report that modulation of DDR pathways is crucial for effective CHIKV infection. This work also shows that there is interaction of CHIKV-nsP2 with two crucial host factors, Chk2 and Chk1 for efficient viral infection. Interestingly, CHIKV infection was found to cause DNA damage and arrest cell cycle in G1 and G2 phases to facilitate viral infection. This information might facilitate to develop effective therapeutics for the control of the CHIKV infection in future.